Contrave and GLP-1: Combination Weight Loss Therapy | Harbor

The weight-loss medication landscape has shifted dramatically. GLP-1 receptor agonists have become the dominant force in obesity pharmacotherapy, delivering weight reductions that earlier drugs could only promise. But for the millions of patients who plateau on a GLP-1, respond partially, or simply can't afford to stay on one indefinitely, a practical question keeps surfacing: can you add Contrave to the mix? Contrave and GLP-1s act through fundamentally different mechanisms, targeting separate drivers of overeating. Here's what the science actually says right now and how to think about combination therapy if you're weighing your options.

How GLP-1 Receptor Agonists Drive Weight Loss

To understand why adding Contrave to a GLP-1 might work, you first need to understand what each drug does on its own. GLP-1 receptor agonists, the class that includes semaglutide and tirzepatide, mimic a gut hormone called glucagon-like peptide-1. When you eat, your intestines naturally release GLP-1, which signals your brain that food is on the way. The injectable versions of these drugs amplify that signal far beyond what your body produces on its own.

The effects cascade through multiple systems. In the hypothalamus, GLP-1 receptor activation suppresses appetite by modulating hunger and satiety hormones. GLP-1 RAs decrease ghrelin (the hormone that drives hunger) while enhancing satiety signals from peptide YY and cholecystokinin. The result is a powerful dampening of the physiological urge to eat. GLP-1s slow gastric emptying. Food stays in your stomach longer, so you feel full sooner and remain full for longer after meals. This effect is dose-dependent, with higher doses producing more pronounced delays in stomach emptying.

lifestyle modification program tracking shown by bare feet standing on a scale with a measuring tape on a light wood floor

The metabolic benefits extend beyond appetite. GLP-1 RAs enhance insulin secretion, reduce glucagon release, lower triglycerides and LDL cholesterol, and reduce inflammation in fat tissue. For patients with type 2 diabetes and obesity, these drugs address multiple pathologies simultaneously. In clinical trials, semaglutide 2.4 mg (the dose used in Wegovy) produces average weight loss of approximately 15% of total body weight over 68 weeks. Tirzepatide, which adds GIP receptor agonism to GLP-1 activity, has shown even greater reductions, up to 22.5%, in the SURMOUNT trials. These are transformative numbers that older anti-obesity medications never approached.

But there's a gap in the GLP-1 story that rarely gets enough attention: these drugs primarily target homeostatic hunger, the biological drive to eat because your body needs energy. They're less effective at addressing hedonic eating, the drive to eat for pleasure, comfort, or emotional regulation, even when you're physically full. Hedonic food intake activates ventral tegmental area dopamine (VTADA) neurons, which sustain continued consumption even when GLP-1 receptor signaling is working to suppress appetite. GLP-1s are fighting against a powerful reward circuit that can partially override their effects. This is precisely where Contrave enters the conversation.

What Contrave Does Differently: Targeting the Reward System

Contrave combines two well-established medications, naltrexone (an opioid receptor antagonist) and bupropion (a dopamine and norepinephrine reuptake inhibitor), in a single extended-release tablet. The FDA approved it for chronic weight management in September 2014.

The combination targets appetite regulation through a mechanism entirely distinct from GLP-1s. In the hypothalamus, bupropion stimulates pro-opiomelanocortin (POMC) neurons in the arcuate nucleus. These neurons produce alpha-melanocyte-stimulating hormone (alpha-MSH), which activates the melanocortin-4 receptor (MC4R), leading to decreased food intake and increased energy expenditure. However, POMC neurons also produce beta-endorphin, which loops back and inhibits those same neurons, applying the brakes on their own appetite-suppressing activity.

This is where naltrexone becomes critical. As an opioid antagonist, naltrexone blocks the mu-opioid receptor that beta-endorphin uses to shut down POMC signaling. By removing that inhibitory brake, naltrexone allows bupropion's stimulation of POMC neurons to produce a sustained, amplified appetite-suppressing effect. Neither drug achieves this alone. The combination enhances POMC signaling more than either component in isolation.

But Contrave's more distinctive action may be in the mesolimbic reward system. The brain's dopamine-driven circuitry governs cravings, reward-seeking behavior, and the emotional drive to eat. Bupropion increases dopamine availability in reward circuits, while naltrexone blocks opioid-mediated reward signals. Together, they reduce the neurochemical payoff that drives hedonic eating.

Contrave is the most extensively studied anti-obesity medication for its impact on food cravings. Functional MRI data from clinical studies have demonstrated changes in brain activation patterns consistent with increased executive control over food-related decisions. In the 56-week COR trial program, patients showing the greatest reductions in cravings achieved the largest weight losses.

The COR trials, four Phase 3 studies enrolling 4,536 patients, established Contrave's standalone efficacy. At 56 weeks, weight loss ranged from 3.7% to 5.6% of total body weight on an intent-to-treat basis (compared to 1.2%–1.7% for placebo). When combined with intensive behavioral modification in COR-BMOD, weight loss reached 8.1%. Approximately 42% of patients in COR-I achieved at least 5% weight loss, versus 17% on placebo. These numbers are modest compared to GLP-1 outcomes. But the mechanism of action makes Contrave a pharmacologically logical complement to GLP-1 therapy.

The Combination Study: What the Data Actually Shows

The available evidence or theoretical perspectives on the effectiveness of combining different anti-obesity medications versus monotherapy come from a retrospective cohort study conducted at an obesity-specialty clinic in Vancouver, Canada, originally published in the International Journal of Obesity in 2024. The study tracked 415 adults with a BMI of 30 or higher who were prescribed GLP-1 analogue therapy. Of these, 320 continued on GLP-1 monotherapy while 95 (22.9%) received add-on bupropion/naltrexone. The researchers measured total body weight loss (TBWL) at 6 and 12 months after the addition of the second medication. Patients on GLP-1 monotherapy achieved a mean weight loss of 11.42 kg (approximately 9.6% TBWL) at 12 months. Among those who received add-on bupropion/naltrexone, the combination resulted in additional weight loss beyond that achieved with GLP-1 alone.

This study was retracted by the International Journal of Obesity in December 2025. Retraction does not necessarily mean the findings are fabricated. Retractions can occur for a range of reasons, including methodological concerns or questions about data integrity. However, the retraction means these specific results should be treated as preliminary and unconfirmed. No randomized controlled trial has yet validated the combination.

Separate from that study, an exploratory analysis from the Contrave clinical trial program found that naltrexone/bupropion was safe and effective for weight loss in patients with type 2 diabetes who were concurrently taking GLP-1 receptor agonists. While this wasn't a head-to-head combination study, it confirmed that the drugs can be co-prescribed without apparent safety red flags in a diabetic population.

Safety Considerations: What Clinicians and Patients Need to Know

The factors clinicians consider when prescribing combination weight-loss therapies include safety profiles, possible drug interactions, and monitoring requirements.

Drug Interaction Profile

Contrave and GLP-1 receptor agonists have a moderate interaction classification. They act through entirely different receptor systems, which reduces the risk of pharmacodynamic overlap. There are no known direct pharmacokinetic interactions. Neither drug meaningfully alters the absorption, metabolism, or clearance of the other.

However, both drug classes can cause gastrointestinal side effects. GLP-1 agonists commonly produce nausea (particularly during dose titration), and Contrave's most frequent adverse effect is also nausea (reported in 32.5% of patients in the COR trials). Constipation (19.2%), headache (17.6%), and vomiting (10.7%) are also common side effects of Contrave. The potential for compounded GI discomfort when both are taken simultaneously is a legitimate clinical concern, though the specific combination has not been systematically studied for additive side-effect burden.

healthy lifestyle support tools including dumbbells, a jump rope, fresh vegetables, fruit, and oats on a two-tone background

Contrave-Specific Risks

Contrave carries an FDA black box warning for suicidal thoughts and behaviors, attributable to the bupropion component. This warning applies broadly to bupropion-containing medications and is based on increased suicidality observed in children, adolescents, and young adults in antidepressant trials. Patients should be monitored for mood changes, particularly during the first few months of treatment.

Other Contrave-specific considerations include seizure risk (bupropion lowers the seizure threshold), contraindication in patients with uncontrolled hypertension, and absolute contraindication in patients with opioid dependence or those taking opioid medications. The naltrexone component will precipitate withdrawal in opioid-dependent individuals and will block the analgesic effects of opioid pain medications.

The Lack of Combination-Specific Safety Data

The most honest assessment of the safety profile is that we don't fully know it yet. No randomized controlled trial has studied the specific combination of Contrave plus a GLP-1 with safety as a primary endpoint. The available evidence, the retracted retrospective study, and the exploratory analyses suggest no alarming signals, but the absence of evidence is not evidence of absence. Any decision to combine these medications should involve a physician who can evaluate individual risk factors, monitor for adverse effects, and adjust treatment accordingly.

The Weight Regain Problem And Why Combination Therapy May Matter More Than You Think

One of the most significant challenges in obesity pharmacotherapy is what happens when you stop. Weight regain after GLP-1 discontinuation is a near-certainty without intervention. A 2025 systematic review and meta-analysis found that discontinuation of GLP-1 receptor agonists resulted in an average weight regain of 5.63 kg. The numbers were worse for the most potent agents: patients who stopped semaglutide or tirzepatide regained an average of 9.69 kg. The landmark STEP 1 extension trial showed that within one year of semaglutide discontinuation, participants regained approximately two-thirds of the weight they had lost.

Platforms like Harbor are already structured around this kind of forward-thinking approach to weight management. Harbor pairs physician-guided GLP-1 therapy with registered dietitian support, specifically designed to help patients transition off medications while maintaining their results, an approach that aligns with emerging evidence that planned, supported treatment transitions yield better long-term outcomes than indefinite medication use or abrupt discontinuation.

Practical Guidance: What to Discuss With Your Doctor

If you're considering whether Contrave might complement your current GLP-1 therapy, here are the key points to raise with your prescribing physician.

If you've plateaued on a GLP-1, combination therapy may help break through the stall. The Vancouver cohort data, even with its retraction caveat, showed that patients who weren't responding adequately to GLP-1 monotherapy gained an additional 4% TBWL after adding bupropion/naltrexone. Ask your doctor whether your plateau might be driven by reward-based eating patterns rather than inadequate appetite suppression.
If you're planning to transition off a GLP-1, whether for cost, side effects, or personal reasons, Contrave may serve as a bridge medication. The real-world maintenance data suggest that oral anti-obesity medications, including bupropion, can help sustain weight loss achieved with GLP-1 therapy. A planned transition is vastly preferable to abrupt discontinuation.
If cravings are your primary challenge, and your GLP-1 controls your physical hunger but you still find yourself eating for emotional or reward-seeking reasons, Contrave's mechanism specifically addresses that gap. It's the best-studied anti-obesity drug for craving reduction, with functional neuroimaging data supporting its effects on brain reward circuitry.
If cost is a concern, Contrave is available in generic form (naltrexone/bupropion ER) and is substantially less expensive than branded GLP-1 injectables. For patients whose insurance doesn't cover GLP-1s or who face high copays, a combination or transition strategy involving Contrave may improve both outcomes and affordability.

Current guidelines, expert consensus, and professional recommendations regarding the use of combination pharmacotherapy for obesity are important. Before starting any combination, your physician should review your full medication list for interactions, assess seizure risk factors (relevant to the bupropion component), confirm you're not taking opioid medications, and establish a monitoring plan for mood-related side effects.

The pharmacological logic for combining Contrave with a GLP-1 is sound, the early clinical signals are encouraging, but the evidence base is not yet robust enough for broad guideline-level recommendations. GLP-1s targeting satiety and metabolic pathways, Contrave targeting the reward system and cravings.

What we don't have is a large, randomized, placebo-controlled trial that prospectively studies the specific combination. That trial needs to happen, and the retraction of the Vancouver study makes it even more urgent. In the meantime, clinicians are making individualized decisions based on the available evidence, their clinical judgment, and their patients' specific needs. The combination is not reckless. But it is off-label, and it requires a physician who understands both drug classes and can monitor appropriately.

weight management program progress tracked as a person wraps a measuring tape around their midsection over a white t-shirt

Weight management is not a one-drug problem. Obesity is a complex, chronic, neurobiological disease driven by overlapping systems. The most effective long-term treatment strategies will almost certainly involve combinations that address multiple drivers simultaneously, supported by clinical guidance and structured plans for sustainability. The Contrave-plus-GLP-1 conversation is an early chapter in that story, and it's one worth having with your doctor.

Sources: